Journal article icon

Journal article

The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management

Abstract:
Pathogenic germline exonuclease domain (ED) variants of POLE and POLD1 cause the Mendelian dominant condition polymerase proof-reading associated polyposis (PPAP). We aimed to describe the clinical features of all PPAP patients with probably pathogenic variants. We identified patients with a variants mapping to the EDs of POLE or POLD1 from cancer genetics clinics, a colorectal cancer (CRC) clinical trial, and systematic review of the literature. We used multiple evidence sources to separate ED variants into those with strong evidence of pathogenicity and those of uncertain importance. We performed quantitative analysis of the risk of CRC, colorectal adenomas, endometrial cancer or any cancer in the former group. 132 individuals carried a probably pathogenic ED variant (105 POLE, 27 POLD1). The earliest malignancy was colorectal cancer at 14. The most common tumour types were colorectal, followed by endometrial in POLD1 heterozygotes and duodenal in POLE heterozygotes. POLD1-mutant cases were at a significantly higher risk of endometrial cancer than POLE heterozygotes. Five individuals with a POLE pathogenic variant, but none with a POLD1 pathogenic variant, developed ovarian cancer. Nine patients with POLE pathogenic variants and one with a POLD1 pathogenic variant developed brain tumours. Our data provide important evidence for PPAP management. Colonoscopic surveillance is recommended from age 14 and upper-gastrointestinal surveillance from age 25. The management of other tumour risks remains uncertain, but surveillance should be considered. In the absence of strong genotype–phenotype associations, these recommendations should apply to all PPAP patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10689-021-00256-y
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1007/s10689-021-00256-y
Publication website:
https://www.research.ed.ac.uk/files/226616788/s10689_021_00256_y.pdf

Authors

More by this author
Role:
Author
ORCID:
0000-0002-9670-2263
More by this author
Role:
Author
ORCID:
0000-0003-3962-389X
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0003-4390-8767
More by this author
Role:
Author
ORCID:
0000-0001-5041-8163
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-2298-5125


More from this funder
Funder identifier:
10.13039/100013791
Grant:
18PG0010
More from this funder
Funder identifier:
10.13039/501100000289
Grant:
Programme award
More from this funder
Funder identifier:
10.13039/100010663
Grant:
EVOCAN


Publisher:
Springer
Journal:
Familial Cancer More from this journal
Volume:
21
Issue:
2
Pages:
197-209
Publication date:
2021-05-05
DOI:
EISSN:
1573-7292
ISSN:
1389-9600


Language:
English
Keywords:
Pubs id:
1175178
Local pid:
pubs:1175178
Source identifiers:
W3158210605
Deposit date:
2026-03-24
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP